Faruqi and Faruqui, LLP Logo
Share this page

Antares Pharma, Inc. (ATRS)

NASDAQ:ATRS

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc. (“Antares” or the “Company”) (NASDAQ:ATRS) of the December 22, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Antares stock or options between December 21, 2016 and October 12, 2017 and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Antares securities between December 21, 2016 and October 12, 2017 (the “Class Period”).  The case, Smith v. Antares Pharma, Inc. et al., No. 2:17-cv-08945 was filed on October 23, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Antares
had provided insufficient data to the U.S. Food and Drug Administration (“FDA”) in connection with its New Drug Application for Xyosted, the Company’s testosterone replacement drug; (2) accordingly, Antares had overstated the approval prospects for Xyosted; and (3) as a result of the foregoing, Antares’s public statements were materially false and misleading at all relevant times.

Specifically, on October 12, 2017, Antares disclosed that on October 11, 2017, the Company received a letter from the FDA stating that the agency had “identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments” for Xyosted.

After the announcement, Antares’ share price fell from $3.73 per share on October 12, 2017 to a closing price of $2.32 on October 13, 2017—a $1.41 or a 37.8% drop.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Antares Pharma, Inc. (ATRS)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 10/24/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.